PLASMA SEPARATING MICROFLUIDIC DEVICE
20210260579 · 2021-08-26
Inventors
- Niclas ROXHED (Bromma, SE)
- Göran STEMME (Lidingö, SE)
- Gabriel LENK (Freiburg, DE)
- Wouter VAN DER WIJNGAART (Sollentuna, SE)
- Jonas HANSSON (STOCKHOLM, SE)
Cpc classification
B01L2400/0418
PERFORMING OPERATIONS; TRANSPORTING
B01L3/502753
PERFORMING OPERATIONS; TRANSPORTING
B01L2200/025
PERFORMING OPERATIONS; TRANSPORTING
B01L3/502738
PERFORMING OPERATIONS; TRANSPORTING
B01L3/50273
PERFORMING OPERATIONS; TRANSPORTING
B01L2200/0684
PERFORMING OPERATIONS; TRANSPORTING
B01L2300/0864
PERFORMING OPERATIONS; TRANSPORTING
B01L2400/0677
PERFORMING OPERATIONS; TRANSPORTING
G01N1/4077
PHYSICS
B01L2300/161
PERFORMING OPERATIONS; TRANSPORTING
International classification
Abstract
A capillary driven microfluidic device with blood plasma separation means that can be used to separate, meter and transfer a blood sample. The blood separation means can be arranged as a capillary pump by the configuration of a porous membrane and the microfluidic device.
Claims
1-11. (canceled)
12. A method of preparing and transporting a sample from whole blood comprising the steps of: (i) arranging in a microfluidic device, a porous blood plasma separating membrane in an acute angle with a hydrophilic surface of a support structure; (ii) applying at least 30 μl whole blood to an upper surface of the membrane and admitting separation of plasma through the membrane; (iii) admitting a wedge-shaped space between the membrane and the support structure gradually be filled with separated plasma; and (iv) filling a capillary channel in fluid communication with said space and metering a defined volume of separated plasma.
13. (canceled)
14. (canceled)
15. (canceled)
16. The method of claim 12, further comprising cancelling fluid communication between the wedge chamber and the capillary channel by pinching off excess plasma from the defined volume in the capillary channel.
17. The method of claim 12, further comprising cancelling the fluid communication between the wedge-shaped space and capillary channel by dissolving a dissolvable valve at the capillary channel inlet.
18. The method of claim 12, further comprising dissolving a second dissolvable valve at the outlet of the capillary channel.
19. The method of claim 12, comprising transporting the metered volume of separated plasma to form a volume defined plasma spot.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0073]
[0074]
[0075]
DETAILED DESCRIPTION OF EMBODIMENTS
[0076] In the following, a detailed description of embodiments of the invention is disclosed.
Device Fabrication
[0077] The microfluidic layer consists of hydrophilic Xerox copier transparencies (003R96002 Type C, Xerox Co. Ltd., USA) and a capillary spacer tape (IVD 090448PV1.001/09, Tesa GmbH, Germany). The different layers were structured separately with a cutting plotter (CE5000, Graphtec America Inc., USA) and laminated together with a laminator (H600, GBC Inc., USA). A liquid PVA solution was prepared from PVA granule (Mowiol® 4-88 Mw ˜31,000, Sigma Aldrich Inc., USA) by dissolving it in DI water and was then spin-coated onto silicon wafers and dried to form thin dissolvable films. The film thickness controlling the dissolving time was fitted to the filtration times required to fill the plasma volume in the metering channel [13]. The dissolvable films were laminated to the microfluidic layer at the openings in the bottom of the channel forming the two dissolvable valves. The microfluidic layer was then attached to the chip backing holding the paper patches (Whatman 903, GE Healthcare, USA) which were used as capillary substrate to absorb the excess plasma and the metered plasma. A 9×9 mm.sup.2 large square of the filtration membrane (SG membrane, from iPOC, Canada) was attached to the inlet of the chip so that the filter forms a capillary wedge structure together with the channel bottom. For attaching the filtration membrane to the chip, double sided adhesive tape (IVD 090448PV1.001/09, Tesa GmbH, Germany) was used.
Filter to Channel Interface Testing
[0078] To study the liquid connection formation between the filter and the capillary channel, the wedge structure was observed by filming the device from the side and through the transparent bottom.
Plasma Extraction Efficiency Testing
[0079] For measuring the extraction efficiency of the filtration membrane, capillary channels without metering function were used (no dissolving valves were used) as seen in the device in
[0080] For the proof-of-concept, 50 μl of fresh capillary blood from a fingerprick was applied to a chip as shown in
[0081] The device is shown in
[0082] Referring to
[0083] The plasma extraction in the test device without dissolvable valves, seen in
[0084] Applying at least 30 μl of whole blood to the plasma separation membrane resulted in plasma filling of the microchannel. Applying less than 30 μl is insufficient for channel filling, most likely because of the dead volume under the membrane and the dead volume of the filtration membrane itself.
[0085] The wedge structure formed between the plasma filter and the channel bottom provides a good capillary contact between the filter and the channel. It is clearly observable how separated plasma propagates from the narrowest part of the wedge structure where the capillary force is the highest and gradually fills up to the channel inlet.
Volume Metered Plasma Extraction Testing
[0086] As a next step. A plasma extraction and metering microfluidic chip is formed, see
[0087] It can be concluded that the present invention, provides an easy-to-use sampling device, which is able to (a) separate plasma from unprocessed human whole blood and (b) meter a defined volume of the plasma for further processing or downstream analysis. The completely autonomous working principle of the chip enables new possibilities by reducing required sample volumes, allowing point-of-care plasma extraction and offering an alternative to venous blood processing by centrifugation. This is highly relevant for clinical laboratory analysis but especially in the field of therapeutic drug monitoring and drug development where the demonstrated principle can help to eases the collection of high quality data while being beneficial for patients.